These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 29494928)

  • 21. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
    Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
    Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
    Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
    Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
    Usuki K; Tojo A; Maeda Y; Kobayashi Y; Matsuda A; Ohyashiki K; Nakaseko C; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Okamoto S; Oritani K; Okada M; Usui N; Nagai T; Amagasaki T; Wanajo A; Naoe T
    Int J Hematol; 2012 Apr; 95(4):409-19. PubMed ID: 22359103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
    Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
    Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
    Korkmaz S; Dal MS; Berber I; Sahin DG; Dogu MH; Ayyildiz O; Nizam I; Albayrak M; Esen R; Namdaroglu S; Sencan M; Akay OM; Hacioglu S; Yildirim R; Eser A; Tombak A; Pala C; Ilhan O
    Geriatr Gerontol Int; 2015 Jun; 15(6):729-35. PubMed ID: 25257190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
    Tyler T
    Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
    Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
    [No Abstract]   [Full Text] [Related]  

  • 32. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
    Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R
    Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
    Bettiol A; Marconi E; Lombardi N; Crescioli G; Gherlinzoni F; Walley T; Vannacci A; Chinellato A; Giusti P
    Clin Drug Investig; 2018 Sep; 38(9):837-844. PubMed ID: 30043130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
    Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
    Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Hehlmann R; Cortes JE; Zyczynski T; Gambacorti-Passerini C; Goldberg SL; Mauro MJ; Michallet M; Simonsson B; Williams LA; Gajavelli S; DeGutis I; Sen GP; Paquette RL
    Am J Hematol; 2019 Jan; 94(1):46-54. PubMed ID: 30290003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
    Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
    Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
    Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
    Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.